STAT3 and neoplasm: Since STAT3 signaling is regulated by molecules such as miRNAs, TLRs, and GPCRs, small‐molecule inhibitors that selectively target these pathways may effectively suppress STAT3 activity, thereby reducing tumor progression and inflammation.